Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $35
Morgan Stanley analyst Matthew Harrison maintains bluebird bio (NASDAQ:BLUE) with a Equal-Weight and lowers the price target from $36 to $35.
Bluebird Bio To Resume Zynteglo Gene Therapy Marketing In Europe After Positive Recommendation From PRAC
European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has concluded that the benefit-risk of Bluebird Bio Inc's (NASDAQ: BLUE) Zynteglo (betibeglogene autotemcel gene therapy) remains favorable.
Berenberg Downgrades bluebird bio to Hold, Announces $35 Price Target
Berenberg analyst Yun Zhong downgrades bluebird bio (NASDAQ:BLUE) from Buy to Hold and announces $35 price target.
Bluebird bio’s Neurological Disorder Gene Therapy Wins CHMP Backing for Approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorizations for Bluebird bio Inc’s (NASDAQ: BLUE)…